Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

December 27, 2019 • 00:23:35
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?
Critical Care Perspectives in Emergency Medicine
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

Dec 27 2019 | 00:23:35

/

Show Notes

Up to one-third of patients with status epilepticus will not respond to benzodiazepines.  Unfortunately, treatment of benzodiazepine-refractory status epilepticus is not well studied.  The longer seizures persist, the worse patients do.  In this podcast, we discuss the results of the recently completed ESETT trial that evaluated three anticonvulsant medications for status epilepticus.

You can get CME credit for this episode here!Click here for CME Account Creation Instructions

Other Episodes

Episode 0

May 10, 2021 • 00:39:02
Episode Cover

Early ED Sepsis Care

Over 80% of patients with sepsis receive care in the ED.  Despite evidence demonstrating the benefits of ED sepsis resuscitation, there remains significant controversies...

Listen

Episode 0

October 04, 2022 • 00:25:21
Episode Cover

Does a Restrictive Oxygenation Target Make a Difference in the Post-Arrest Patient?

The care of patients with return of spontaneous circulation following cardiac arrest centers on optimizing oxygenation and ventilation, optimizing hemodynamics, identifying patients that require...

Listen

Episode 0

July 15, 2020 • 00:26:28
Episode Cover

TXA for GI Bleeds? The HALT-IT Trial

The use of tranexamic acid (TXA) has markedly increased since the results of the CRASH-II trial were published.  In addition to its use in...

Listen